GLP-1 Drugs: What Employers Need to Know GLP-1 drugs like Ozempic and Zepbound have gained significant attention in recent years for treating both diabetes and assisting with weight loss
Despite the above preclinical evidence, there is no significant effect on appetite, energy intake or energy expenditure following a GIP acute infusion over a short period
FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain
In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet doses in patients with T2D, 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively
This creates a metabolic environment that overlaps considerably with conditions such as metabolic syndrome and type 2 diabetes
Challenges in CHE Implementation for CHE testing and multidisciplinary team One of the greatest challenges in the clinical management of CHE is the low rate of screening implementation
